Volume 143, Issue 2, Pages (November 2016)

Slides:

Advertisements

Similar presentations

Port-site recurrence in a patient undergoing robotic hysterectomy and lymph node dissection for endometrioid adenocarcinoma of the uterus Ioannis Alagkiozidis,

Advertisements

Nicoletta Colombo, Martin Gore

Volume 144, Issue 1, Pages (January 2017)

Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin Andrés Poveda, Isabelle Ray-Coquard, Ignacio Romero,

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Volume 147, Issue 2, Pages (November 2017)

Volume 150, Issue 1, Pages (July 2018)

Volume 148, Issue 1, Pages (January 2018)

Are patients willing to travel for better ovarian cancer care?

Volume 148, Issue 1, Pages (January 2018)

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

Volume 148, Issue 1, Pages (January 2018)

Volume 146, Issue 3, Pages (September 2017)

Volume 150, Issue 3, Pages (September 2018)

Pain in cancer survivors; filling in the gaps

Volume 149, Issue 2, Pages (May 2018)

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Vulvar intraepithelial neoplasia: Risk factors for recurrence

Volume 144, Issue 2, Pages (February 2017)

Patient-reported symptoms and performance status before palliative radiotherapy in geriatric cancer patients (octogenarians) Carsten Nieder, Thomas A.

The efficacy of mTORC1/2 inhibition on ovarian cancer stem cells

Volume 152, Issue 1, Pages (January 2019)

Volume 141, Issue 2, Pages (May 2016)

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

Volume 151, Issue 1, Pages (October 2018)

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

Volume 148, Issue 1, Pages (January 2018)

Volume 136, Issue 2, Pages (February 2015)

The development and use of vascular targeted therapy in ovarian cancer

Supportive care plans: Linking patient-reported outcomes to evidence-based supportive care across the cancer continuum E.E. Stevens, J.N. Bottsford-Miller,

Volume 145, Issue 2, Pages (May 2017)

Volume 142, Issue 3, Pages (September 2016)

National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence J. Chino, J.R. Foote,

Volume 146, Issue 1, Pages (July 2017)

Volume 91, Issue 3, (December 2003)

Volume 152, Issue 1, Pages (January 2019)

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 147, Issue 2, Pages (November 2017)

Volume 152, Issue 1, Pages (January 2019)

Laparoscopic staging for stage I epithelial ovarian cancer: Analysis of the National Cancer Data Base A. Melamed, J.T. Clemmer, N.L. Keating, J.D. Wright,

The origins of multidisciplinary cancer care

Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum A. Ellis, M.K. Frey, L.M. Koontz, S. Shyne,

Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Volume 152, Issue 1, Pages (January 2019)

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Volume 147, Issue 1, Pages (October 2017)

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

The complex interaction of cancer surgery, complications, and patient-reported outcomes: A single score is not enough K.M. Doll, E.L. Barber, J.T. Bensen,

Volume 142, Issue 2, Pages (August 2016)

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Volume 147, Issue 3, Pages (December 2017)

Volume 152, Issue 1, Pages (January 2019)

Volume 130, Issue 1, Pages (July 2013)

Full inguinofemoral lymphadenectomy after positive sentinel inguinofemoral lymph node is associated with greater overall survival in patients with stage.

Volume 152, Issue 1, Pages (January 2019)

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

Differences in patterns of care and outcomes between grade II and grade III molecularly defined 1p19q co-deleted gliomas Debra Nana Yeboa, James B. Yu,

Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer M. Dandapani, B.L. Seagle, R. Samuelson,

Volume 130, Issue 1, Pages (July 2013)

Volume 152, Issue 1, Pages (January 2019)

Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma? L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Volume 115, Issue 1, Pages (October 2009)

Volume 153, Issue 3, Pages (June 2019)

Volume 154, Issue 1, Pages (July 2019)

Presentation transcript:

Volume 143, Issue 2, Pages 246-251 (November 2016) A comparison of overall survival with 40 and 50mg/m2 pegylated liposomal doxorubicin treatment in patients with recurrent epithelial ovarian cancer: Propensity score-matched analysis of real-world data Masahiko Nakayama, Hisanori Kobayashi, Tomihiro Takahara, Yukiko Nishimura, Koji Fukushima, Kazutake Yoshizawa Gynecologic Oncology Volume 143, Issue 2, Pages 246-251 (November 2016) DOI: 10.1016/j.ygyno.2016.08.331 Copyright © 2016 The Authors Terms and Conditions

Fig. 1 Patient flow diagram. Gynecologic Oncology 2016 143, 246-251DOI: (10.1016/j.ygyno.2016.08.331) Copyright © 2016 The Authors Terms and Conditions

Fig. 2 Overall survival of full dataset; green, PLD 50mg/m2; blue, PLD 40mg/m2. Gynecologic Oncology 2016 143, 246-251DOI: (10.1016/j.ygyno.2016.08.331) Copyright © 2016 The Authors Terms and Conditions

Fig. 3 Overall survival of propensity-score matched dataset; green, PLD 50mg/m2; blue, PLD 40mg/m2. Gynecologic Oncology 2016 143, 246-251DOI: (10.1016/j.ygyno.2016.08.331) Copyright © 2016 The Authors Terms and Conditions